Beyond opioids: FDA-approved suzetrigine offers hope for acute pain management.
作者信息
Khan Aleeza, Irshad Maryam, Javed Zara, Naz Zahra, Fatima Mahnoor
机构信息
Department of Medicine, Nishtar Medical College, Nishtar Medical University, Multan, Pakistan.
Department of Medicine, Shaheed Ziaur Rahman Medical College, Rajshahi Medical University, Bogura, Bangladesh.
出版信息
Ann Med Surg (Lond). 2025 Jun 10;87(7):4023-4025. doi: 10.1097/MS9.0000000000003462. eCollection 2025 Jul.
Abstract
摘要
相似文献
1
Beyond opioids: FDA-approved suzetrigine offers hope for acute pain management.
Ann Med Surg (Lond). 2025 Jun 10;87(7):4023-4025. doi: 10.1097/MS9.0000000000003462. eCollection 2025 Jul.
2
Pharmacology Update: Suzetrigine: A Novel NaV1.8 Sodium Channel Inhibitor for Acute Pain Management.
Am J Hosp Palliat Care. 2025 Jul 2:10499091251353455. doi: 10.1177/10499091251353455.
3
Suzetrigine: A Novel Non-Opioid Analgesic for Acute Pain Management-A Review.
Drugs Drug Candidates. 2025 Sep;4(3). doi: 10.3390/ddc4030032. Epub 2025 Jul 4.
4
Suzetrigine, a Nonopioid Na V 1.8 Inhibitor for Treatment of Moderate-to-severe Acute Pain: Two Phase 3 Randomized Clinical Trials.
Anesthesiology. 2025 Jun 1;142(6):1085-1099. doi: 10.1097/ALN.0000000000005460. Epub 2025 Mar 21.
5
Suzetrigine Approval Breaks a 25-Year Silence: A New Era in Non-Opioid Acute Pain Management.
J Pain Res. 2025 Jun 6;18:2805-2808. doi: 10.2147/JPR.S526851. eCollection 2025.
6
Suzetrigine, a Non-Opioid Na1.8 Inhibitor With Broad Applicability for Moderate-to-Severe Acute Pain: A Phase 3 Single-Arm Study for Surgical or Non-Surgical Acute Pain.
J Pain Res. 2025 Mar 25;18:1569-1576. doi: 10.2147/JPR.S509144. eCollection 2025.
7
Suzetrigine (VX-548): Bidding goodbye to opioids: The latest oral non-opioid analgesic for acute pain.
Saudi J Anaesth. 2025 Jul-Sep;19(3):384-386. doi: 10.4103/sja.sja_366_25. Epub 2025 Jun 16.
8
Suzetrigine: The first Nav1.8 inhibitor approved for the treatment of moderate to severe acute pain.
Drug Discov Ther. 2025 Mar 6;19(1):80-82. doi: 10.5582/ddt.2025.01010. Epub 2025 Feb 27.
9
Suzetrigine: A novel selective sodium channel inhibitor for pain.
Am J Health Syst Pharm. 2025 Aug 18. doi: 10.1093/ajhp/zxaf219.
本文引用的文献
1
Personalised cancer vaccines and new regulatory struggles.
Lancet Oncol. 2025 Mar;26(3):265. doi: 10.1016/S1470-2045(25)00096-8.
2
Pharmacology and Mechanism of Action of Suzetrigine, a Potent and Selective Na1.8 Pain Signal Inhibitor for the Treatment of Moderate to Severe Pain.
Pain Ther. 2025 Apr;14(2):655-674. doi: 10.1007/s40122-024-00697-0. Epub 2025 Jan 8.
3
Artificial intelligence alphafold model for molecular biology and drug discovery: a machine-learning-driven informatics investigation.
Mol Cancer. 2024 Oct 5;23(1):223. doi: 10.1186/s12943-024-02140-6.
4
Opioid crisis: addiction, overprescription, and insufficient primary prevention.
Lancet Reg Health Am. 2023 Jul 12;23:100557. doi: 10.1016/j.lana.2023.100557. eCollection 2023 Jul.
5
The opioid epidemic: A worldwide exploratory study using the WHO pharmacovigilance database.
Addiction. 2023 Apr;118(4):771-775. doi: 10.1111/add.16081. Epub 2022 Nov 22.
Zotero 插件